Skip to content

Diabetes Coaching Study

Diabetes Coaching Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02066831
Acronym
DCS
Enrollment
202
Registered
2014-02-20
Start date
2014-02-28
Completion date
2015-12-31
Last updated
2016-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Brief summary

The purpose of the study is to compare the effect of telemedical coaching versus telemedical control on HbA1c, weight, BMI, blood pressure, blood lipids, medication, nutrition, physical activity and quality of life in type 2 diabetes patients with poor glycaemic control.

Interventions

OTHERTelemedicine

Sponsors

German Institute for Telemedicine and Health Promotion
CollaboratorOTHER
West German Center of Diabetes and Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
25 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

* type 2 diabetes mellitus * hemoglobin A1c (HbA1c) \>7.5% * at leat two different antidiabetic drugs * body mass index \>27kg/m2

Exclusion criteria

* acute infections * diagnosed chronic diseases other than type 2 diabetes and hypertension, e.g. cancer, chronic obstructive pulmonary disease (COPD), asthma, dementia, chronic gut diseases, psychoses, liver cirrhosis, (macro-) nephropathy, kidney insufficiency with glomerular filtration rate (eGFR) \< 30ml / min / 1.73 m2 * acute chemotherapy or chronic cortisol treatment * smoking cessation for less than 3 months and or planned smoking cessation during study * known intolerance of any ingredient of Almased (especially soy protein) * pregnancy or breast feeding, lack of contraception (women) * other study participation in the last 6 months prior to study start

Design outcomes

Primary

MeasureTime frameDescription
HbA1c12 monthsDifference in HbA1c (at end of study vs. baseline) between the groups

Secondary

MeasureTime frameDescription
antidiabetic medication12 monthsDifference in antidiabetic medication (at end of study vs. baseline) between the groups
Cardiovascular risk parameters (blood pressure, blood lipids)12 monthsDifference in cardiovascular risk parameters (i.e. blood pressure, blood lipids) (at end of study vs. baseline) between the groups
weight12 monthsDifference in weight (at end of study vs. baseline) between the groups
nutrition12 monthsDifference in nutrition (at end of study vs. baseline) between the groups
quality of life12 monthsDifference in quality of life (at end of study vs. baseline) between the groups
physical activity (step count)12 monthsDifference in physical activity (at end of study vs. baseline) between the groups

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026